louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06987110: Transverse Thoracic Plane Block, Midpoint Transverse Process Plane to Pleura Block and Erector Spinae Plane Block for Analgesia in Patients Undergoing Thoracoscopic Sympathectomy
Official title: A Randomized Clinical Trial Comparing Transverse Thoracic Plane Block, Midpoint Transverse Process Plane to Pleura Block and Erector Spinae Plane Block for Analgesia in Patients Undergoing Thoracoscopic Sympathectomy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Transverse Thoracic Plane Block
Midpoint Transverse Process Plane to Pleura Block
Erector Spinae Plane Block
Analgesia
Thoracoscopic Sympathectomy
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-05-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the transversus thoracic muscle plane block (TTPB), midtransverse to pleura block (MTPB), and erector spinae plane block (ESPB) for postoperative analgesia in patients undergoing thoracoscopic sympathectomy.

Detailed description: Thoracoscopic sympathectomy is a well-established procedure for the treatment of various hyperhidrosis disorders and certain vascular conditions, involving the division of sympathetic nerve fibers in the thoracic cavity.

The erector spinae plane block (ESPB) is an interfascial regional anesthesia block for thoracic analgesia which can be performed by superficial or deep needle approach.

The mid-transverse to pleura block (MTPB) was first described as a modified paravertebral block.

Transversus thoracic muscle plane block (TTPB) is a newly developed technique in which LA is injected into the fascial plane between the transversus thoracic muscle and the internal intercostal muscles for blocking the anterior cutaneous branches of intercostal nerves from thoracic (Th) 2 to Th 6.

Eligibility criteria: Inclusion Criteria:

* Age from 18 to 65 years.
* Both sexes.
* American Society of Anesthesiology (ASA) physical status I-II.
* Scheduled for thoracoscopic sympathectomy

Exclusion Criteria:

* Coagulopathy.
* History of opiate abuse.
* Pre-existing chronic pain.
* Allergy to local anesthetics or analgesics.
* Infection at the site of injection.
* Mental or neurological disorders.
* Pregnancy

Primary outcomes:
measure: Time to the 1st rescue analgesia
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: Total morphine consumption
timeFrame: 24 hours postoperatively
measure: Degree of pain
timeFrame: 24 hours postoperatively
measure: Heart rate
timeFrame: Till the end of surgery (Up to 2 hours)
measure: Mean arterial pressure
timeFrame: Till the end of surgery (Up to 2 hours)
measure: Degree of patient satisfaction
timeFrame: 24 hours postoperatively
measure: Incidence of complications
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT01800110: Influence of Pomegranate Juice Consumption on the Level of Antioxidants in Breast Milk
Official title: Influence of Pomegranate Juice Consumption on the Level of Antioxidants in Breast Milk
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Milk
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2013-02-27
Enrollment: 40
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Many medicinal effects of Pomegranate juices are already known. Mainly known for its anti-viral, anti-bacterial and anti-oxide tendency of pomegranate juice.

Many studies which have demonstrated antioxidant activity of pomegranate juice in the blood and blood cells were published.

In addition, published studies have demonstrated the anti-oxidant activity which inhibit the development of atherosclerosis and stroke, even in patients with diabetes, and its effect of decreasing systolic blood pressure in patients with systemic hypertension.

The purpose of the work is to examine the effect of drinking pomegranate juice on the level of anti-oxidants in human breast milk.

Detailed description: the effect of pomegranate juice consumption on breast milk anti oxidants level.

Eligibility criteria: Inclusion Criteria:

* lactating woman

Exclusion Criteria:

* pomegranate allergy
* diabetes mellitus
* use of other Dietary Supplement

Primary outcomes:
measure: anti oxidant level in human breast milk
timeFrame: at least one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00528710: Efficacy of S-Adenosylmethionine in Fibromyalgia
Official title: Double-Blind, Placebo-Controlled Trial of the Impact of S-Adenosyl-L-Methionine (SAM-e) on the Mood and Other Symptoms in Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fibromyalgia Syndrome
Keywords: S-Adenosylmethionine
Lead sponsor: Deakin University
Sponsor class: OTHER
First posted: 2007-09-12
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fundamentally, the trial aims to conduct a gold-standard test of the clinical impact of SAM-e in the treatment of depressed mood and general symptoms of fibromyalgia (FMS).

As such, salient clinical and pathological parameters will be assessed over an 8-week period in 60 patients who will be provided with either SAM-e or a placebo preparation . On the basis of previous literature, it is hypothesised that patients in the active treatment group will experience moderate but significant improvements across the clinical measures, and that these gains will be significantly greater than any reported in the placebo group. All patients will provide informed consent. All procedures will be conducted under medical supervision and the preparation itself is very safe when used in the manner proposed for the trial


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Fibromyalgia by a medical practitioner

Exclusion Criteria:

* Pregnancy, Manic and hypomanic conditions

Primary outcomes:
measure: Symptom reduction in Fibromyalgia. Specifically we expect a reduction in depressive symptoms, sleep disturbances and gastric disturbances.
timeFrame: Measured at three points in time: pre-trial and at 4 and 8 weeks
Secondary outcomes:
measure: Examination of dose-response data and the nature of the placebo effect in these conditions.
timeFrame: Measured at three points in time: pre-trial and at 4 and 8 weeks
Other outcomes:
Locations:
city: Burwood
country: Australia
facility: Deakin University
state: Victoria
Study officials:
affiliation: Deakin University
name: Gregory A Tooley, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06979310: The Comparative Effectiveness Evaluation of the Impact of Digital Education
Official title: The Comparative Effectiveness Evaluation of the Impact of Digital Education Via Text Message Versus Multimedia Modules on Caregiver Knowledge
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pediatric Cancer
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2025-05-18
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study is being conducted to determine how best to educate caregivers about cancer and its treatment. When caregivers are well-informed, they are more confident in supporting their child through treatment, which can improve treatment adherence.


Eligibility criteria: Inclusion Criteria:

* a known pediatric cancer diagnosis
* Adult caregivers of children with cancer (\<18yo) at time of new patient registration
* Ability to understand and speak Swahili
* If illiterate, availability of a household member who can read Swahili
* Be able to access the messages

Exclusion Criteria:

* any potential participant who is unable to access messages will also be excluded.
* Non cancer pediatric diagnosis

Primary outcomes:
measure: Treatment abandonment rate.
timeFrame: 6 months
Secondary outcomes:
measure: Caregiver knowledge
timeFrame: Baseline, 6 months
measure: Caregiver attitudes
timeFrame: Baseline, 6 months
measure: Perceived behavior control
timeFrame: Baseline, 6 months
measure: Caregiver intention
timeFrame: Baseline, 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Kristin Schroeder Principal Investigator
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01268410: Epidemiology of Respiratory Insufficiency in Critical Care
Official title: Epidemiological Study of Patients With Acute Respiratory Failure Admitted to Brazilian Intensive Care Units
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Respiratory Failure
Keywords: Acute respiratory failure
Acute lung injury
Acute respiratory distress syndrome
Mechanical Ventilation
Non-Invasive Ventilation
Lead sponsor: Hospital Sirio-Libanes
Sponsor class: OTHER
First posted: 2010-12-30
Enrollment: 773
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to intensive care units in Brazil with acute respiratory failure

Brief summary: Acute respiratory failure is a common entity in intensive care units nowadays and is associated with significant morbidity and mortality, thus representing a major health problem. Most of the published epidemiological studies on this condition were performed when modern ventilatory strategies and non-invasive ventilation were not available. Therefore, an actual evaluation on the incidence and outcomes of this syndrome is mandatory. We will perform an observational prospective study of patients admitted with acute respiratory insufficiency in several ICUs in Brazil.


Eligibility criteria: Inclusion Criteria:

* Need for non-invasive or invasive mechanical ventilation for more than 24 hours in the first 48 hours of admission to the intensive care unit.

Exclusion Criteria:

* Tracheostomized patients
* Patients admitted to ICUs for monitoring or in post-operatory of non-complicated surgeries.
* Patients with cancer on terminal stage.

Primary outcomes:
measure: hospital mortality
timeFrame: 15 days
Secondary outcomes:
measure: incidence of acute respiratory failure
timeFrame: 15 days
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Hospital Sirio-Libanes
Study officials:
affiliation: Hospital Sirio-Libanes
name: Luciano CP Azevedo, MD, PhD
role: STUDY_CHAIR
affiliation: Hospital Sirio-Libanes
name: Marcelo Park, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital Sirio-Libanes
name: Guilherme PP Schettino, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Instituto D'Or de Pesquisa e Ensino
name: Marcio Soares, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Instituto D'Or de Pesquisa e Ensino
name: Jorge IF Salluh, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Azevedo LC, Park M, Salluh JI, Rea-Neto A, Souza-Dantas VC, Varaschin P, Oliveira MC, Tierno PF, dal-Pizzol F, Silva UV, Knibel M, Nassar AP Jr, Alves RA, Ferreira JC, Teixeira C, Rezende V, Martinez A, Luciano PM, Schettino G, Soares M; ERICC (Epidemiology of Respiratory Insufficiency in Critical Care) investigators. Clinical outcomes of patients requiring ventilatory support in Brazilian intensive care units: a multicenter, prospective, cohort study. Crit Care. 2013 Apr 4;17(2):R63. doi: 10.1186/cc12594.
Clinical trial NCT00450710: Neuroendocrine Brake for Type 2 Diabetes Mellitus
Official title: Phase IV Study of Neuroendocrine Brake Surgical Procedure for Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes
Lead sponsor: Medtronic - MITG
Sponsor class: INDUSTRY
First posted: 2007-03-22
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Evaluation to determine the safety of two laparoscopic procedures to control T2DM.


Eligibility criteria: Inclusion Criteria:

1. - Male and female between 18 and 65 years.
2. BMI 25.1 - 34.9.
3. Type 2 diabetic patients on oral anti-diabetic agents and/or insulin treatment for a minimum of 12 months prior the enrollment.
4. Diagnosis of T2DM for at least 3 years.
5. Patient has been under routine care of hte study physician or another physician that can supply a reliable medical record for at least 3 years.
6. HbA1c \>/ 7.5 documented for at least 3 months.
7. Stable weight (nor significant weight change (\>3%) over the 3 months prior to enrollment.
8. Stable medication for at least one month prior to enrollment except for diabetes medications which should be stable for at least 3 months prior to enrollment.
9. Ability and willingness to return for all scheduled visits and participate in recommended parameter setting and physician recommended medical/laboratory assessments.

Exclusion Criteria:

1. Prior abdominal surgery, except laparoscopic cholecystectomy.
2. Taking appetite suppressant.
3. Severe eating disorders.
4. Severe pulmonary, renal or cardiac disease.
5. Obese due to a clinically diagnosed endocrine disorder.
6. Subjects with impaired liver function.
7. History of peptic ulcer disease.
8. History of malignant disease.
9. Use of prescription, over the counter or herbal weight loss products.
10. Pregnant or planning on pregnancy while enrolled in study.

Primary outcomes:
measure: Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.
Secondary outcomes:
measure: Evaluate neurohormonal effect in treating T2DM.
measure: Improvement or control of blood glucose levels.
measure: Improvement or control of comorbidities associated with T2DM.
measure: Hormonal effect and effect of the operations on diabetes related and total mortality.
Other outcomes:
Locations:
city: Goiania
country: Brazil
facility: Hospital de Especialidades
Study officials:
affiliation: Medtronic - MITG
name: Noreen A Gannon
role: STUDY_DIRECTOR
affiliation: Hospital de Especialidades
name: Aureo DePaula, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05767710: A Study of the Telerehabiliation Intervention Effect of the Tai Chi Exercise on Elderly With Sarcopenia
Official title: An Alternative Remote Rehabilitation Strategy for the Improvement of Sarcopenia in the Elderly: Tai Chi as an Exercise Form
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sarcopenia
Keywords: sarcopenia
human pose
Lead sponsor: Northeast Normal University
Sponsor class: OTHER
First posted: 2023-03-14
Enrollment: 225
Sex: ALL
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Sarcopenia is an age-related disease characterized by a progressive decrease in skeletal muscle content and loss of muscle function. Tai Chi exercises have been shown to improve skeletal muscle mass in elderly people suffering from sarcopenia. However, offline interventions are a very labor- and financial-intensive approach. Therefore, researchers designed an artificial intelligence-assisted program and Tai Chi exercise format to investigate whether a remote rehabilitation approach could replace face-to-face interventions


Eligibility criteria: Inclusion Criteria:

(1) Patients between the ages of 60-75 years; (2) who meet the screening criteria for sarcopenia in Asia established by AWGS 2019; (3) who have a computer at home (4) who can use a computer or was accompanied by family number who can use a computer.

Exclusion Criteria:

(1) participants taking medications that significantly impact musculoskeletal function (2) participants suffering from respiratory failure or other bodily problems; (3) participants with mental disorders or neurological disorders; (4) patients who participate in other training programs on a regular basis.

Primary outcomes:
measure: Using quantitative CT to investigate the change of skeletal muscle area in sarcopenic elderly.
timeFrame: Month 3
measure: Using a Jamar hydraulic hand dynamometer to investigate change of handgrip in sarcopenic elderly.
timeFrame: Month 3
measure: Using a bioelectrical impedance body composition analyzer with a multifrequency device to investigate the change of relative skeletal muscle mass index in sarcopenic elderly.
timeFrame: Month 3
Secondary outcomes:
measure: Collect participants' self-evaluation of their life state and physical state.
timeFrame: Month 3
measure: Collect video of participants throughout the intervention.
timeFrame: Month 3
Other outcomes:
Locations:
city: Changchun
country: China
facility: Chinese Center of Exercise Epidemiology
state: Jilin
Study officials:
References:
Clinical trial NCT05745610: Shen Hai Long Capsule for Male Asthenospermia
Official title: An Clinical Trial on the Efficacy and Safety of Shen Hai Long Capsule in the Treatment of Male Asthenospermia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men
Keywords: efficacy
safety
Lead sponsor: Zhongnan Hospital
Sponsor class: OTHER
First posted: 2023-02-27
Enrollment: 120
Sex: MALE
Minimum age (years): 22
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men.

Detailed description: To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men: 1) Efficacy index (1) Main efficacy indexes Forward motile sperm ratio (PR) (2) Secondary efficacy indexes 1. Sperm survival rate; 2. Sperm concentration; 3. Normal morphology rate of sperm; 4. Seminal malondialdehyde (MDA) 5. Seminal superoxide dismutase (SOD) 2) Safety indicators

(1) Vital signs; (2) liver and kidney function; (3) blood routine; (4) electrocardiogram; (5) Adverse events.

Eligibility criteria: Inclusion Criteria:

1. Age range from 22 to 50 years old;
2. Patients with mild to moderate asthenospermia, that is, at least two normative semen analyses indicated that 10%≤PR percentage \< 32% and the total number of PR sperm ranged from 5 million to 20 million;
3. At least two standard semen analyses indicated that sperm concentration ≥15×106 /ml; Sperm normal morphology rate ≥4%;
4. No other Chinese and Western drugs for the treatment of oligospermia, weak and malformed spermia have been taken in the past 3 months;
5. The subject voluntarily participates and signs the informed consent.

Exclusion Criteria:

1. Varicocele, ejaculatory duct/seminal vesicle cyst, anti-sperm antibody (+);
2. Genital tract infection: seminal plasmic elastase \> 1000ng/ml or leukocyte semen disease (peroxidase positive cell concentration in semen more than 1×10\^6/mL);
3. Erectile dysfunction, ejaculation disorders;
4. suffer from mental disorders, immune system diseases; Severe impairment of liver and kidney function (serum transaminase ≥2× upper limit of medical reference value, creatinine clearance ≤40ml/min or active stage of chronic kidney disease);
5. Patients with allergic history or constitution to therapeutic drugs;
6. Patients who have taken drugs affecting the study within 3 months, such as antitumor and antiepileptic drugs, etc.

Primary outcomes:
measure: Forward motile sperm ratio (PR)
timeFrame: 12 weeks
Secondary outcomes:
measure: Sperm survival rate
timeFrame: 12 weeks
measure: Sperm concentration
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Zhongnan Hospital of Wuhan University
state: Hubei
Study officials:
affiliation: Wuhan University
name: Yuanzhen Zhang, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02906410: Dynamic Presentation of Calorie Information
Official title: Dynamic Presentation of Calorie Information
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Not Condition-specific
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Carnegie Mellon University
First posted: 2016-09-20
Enrollment: 8544
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Participants will be asked to select a hypothetical lunch from a menu that features entrees, sides, and drinks. Participants will be able to select a maximum of 1 item from each category. Following this meal selection, participants will complete a short survey about their demographics, their estimates of information about the meal and about recommended eating habits.

Detailed description: The presence or absence of calorie labels on the hypothetical lunch menu will be randomly assigned to participants. Participants will first be randomly assigned to either the numeric label survey or the light label survey, and then within that survey, participants will be randomly assigned to either a control (no label), an item-level label, or an item-level and meal-level label condition.

Participants will select a hypothetical lunch from a menu that features entrees, sides, and drinks. Participants will be able to select a maximum of 1 item from each category. Following this meal selection, participants will complete a short survey about their demographics, their estimates of information about the meal and about recommended eating habits.

Eligibility criteria: Inclusion Criteria:

* 18 or older
* US resident

Exclusion Criteria:

* Unable to complete survey on computer

Primary outcomes:
measure: Calories ordered
timeFrame: 5 minutes after presentation of information
Secondary outcomes:
measure: Light category ordered
timeFrame: 5 minutes after presentation of information
measure: Calories per category
timeFrame: 5 minutes after presentation of information
Other outcomes:
measure: Sequence of items selected
timeFrame: 5 minutes after presentation of information
Locations:
Study officials:
affiliation: Postdoctoral Fellow
name: Eric VanEpps, PhD
role: PRINCIPAL_INVESTIGATOR
References: